The FDA has now approved the treatment for transfusion-dependent beta thalassemia as well as sickle cell disease. Pictured is the Food And Drug Administration headquarters in Maryland.
Mandatory Credit: Sarah Silbiger/Getty Images
Stories this photo appears in:
FDA clears first CRISPR treatment for second disease, beta thalassemia
The US Food and Drug Administration has approved a second use for the first CRISPR-based medicine, Casgevy, which was approved in December to treat sickle cell disease.
